Damora Therapeutics (DMRA) vs Oric Pharmaceuticals (ORIC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Damora Therapeutics (DMRA) has outperformed Oric Pharmaceuticals (ORIC) over the past year, gaining 12.9% versus a loss of 14.9%. Over five years, ORIC leads with a -26.0% price change compared with -76.3% for DMRA. Damora Therapeutics is the larger company by market cap ($1.25 billion vs $1.24 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DMRA | ORIC |
|---|---|---|
| Share price | $20.24 | $12.01 |
| Market cap | $1.25B | $1.24B |
| 1-day change | +3.53% | +0.25% |
| YTD return | -12.04% | +46.82% |
| 1-year return | +12.95% | -14.94% |
| 5-year return | -76.33% | -26.00% |
| EPS (TTM) | $-0.25 | $-1.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $38.33 | $14.68 |
| 52-week low | $4.95 | $7.23 |
| Distance from 52-week high | -47.19% | -18.19% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +131.67% | +78.43% |
| Average volume | 540.62K | 1.47M |
| Shares outstanding | 61.74M | 103.65M |
| Employees | 7 | 111 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DMRA has outperformed ORIC by 27.9 percentage points over the past year.
About Damora Therapeutics
DMRA stock →Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Oric Pharmaceuticals
ORIC stock →ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study.
Health Care · Biotechnology: Pharmaceutical Preparations · 111 employees
DMRA vs ORIC FAQ
Which is bigger, Damora Therapeutics or Oric Pharmaceuticals?
Damora Therapeutics (DMRA) is larger, with a market capitalization of $1.25B compared with $1.24B for Oric Pharmaceuticals (ORIC).
Which stock has performed better over the past year, DMRA or ORIC?
DMRA returned +12.95% over the past 12 months, compared with -14.94% for ORIC (price return, excluding dividends). Past performance does not predict future results.
Are Damora Therapeutics and Oric Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.